martedì, 21 marzo 2023
5 Novembre 2018

FDA Approves Frontline Pembrolizumab Regimen for Squamous NSCLC

October 30, 2018 – The FDA has approved first-line pembrolizumab for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC). The approval is based on results from the phase III KEYNOTE-407 trial, in which combining pembrolizumab with chemotherapy reduced the risk of death by 36% compared with chemotherapy alone in patients with metastatic … (leggi tutto)